Overview

Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.

Status:
Withdrawn

Trial end date:
2022-03-31

Target enrollment:

Participant gender:

Summary

This study is designed to test the hypothesis that ticagrelor is superior to clopidogrel, in improving coronary microvascular function, as measured by coronary flow reserve (CFR) in patients with T2DM at high risk of cardiovascular (CV) events undergoing elective PCI.

Phase:

Phase 3

Details

Lead Sponsor:

Region Skane

Collaborators:

AstraZeneca
Hippocrates Research
IHF GmbH - Institut für Herzinfarktforschung
IRW consulting AB

Treatments:

Clopidogrel
Ticagrelor